| 1 | 0.5 mg budesonide effervescent tablet for orodispersible use | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 2 | 1 mg budesonide effervescent tablet for orodispersible use | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 3 | 1mg budesonide effervescent tablet for orodispersible use | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 4 | 2mg budesonide effervescent tablet for orodispersible use | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 5 | 5 mg Montelukast | [1] Montelukast Montelukast | [2] Montelukast sodium
Montelukast sodium
,
Montelukast
💬
| [1] CYSLTR1 CYSLTR1 💬
| [2] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 6 | [BUL 0.5 mg] | - | - | - | - | [1] 98 98 💬
|
| 7 | [BUL 1 mg] | - | - | - | - | [1] 98 98 💬
|
| 8 | [CC-93538] | - | - | - | - | [1] 98 98 💬
|
| 9 | [CDX-0159] | - | - | - | - | [1] 98 98 💬
|
| 10 | [MEDI-563] | - | - | - | - | [5] 44 44, 45, 98, 162, 299 💬
|
| 11 | [MEDI9929 anti-TSLP mAb (AMG157)] | [1] Tezepelumab Tezepelumab | [1] Tezepelumab
Tezepelumab
💬
| [1] TSLP TSLP 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 98 98 💬
|
| 12 | [NA] | - | - | - | - | [34] 3 3, 6, 11, 13, 14, 19, 28, 35, 41, 46, 49, 50, 53, 57, 62, 63, 65, 75, 79, 85, 90, 96, 97, 98, 113, 127, 162, 195, 223, 229, 251, 294, 299, 302 💬
|
| 13 | AK002 | - | - | - | - | [1] 98 98 💬
|
| 14 | Allergy immunotherapy (allergy shots) | - | - | - | - | [1] 98 98 💬
|
| 15 | Alpha-proteinase inhibitor | - | - | - | - | [1] 98 98 💬
|
| 16 | AMG 157 | [1] Tezepelumab Tezepelumab | [1] Tezepelumab
Tezepelumab
💬
| [1] TSLP TSLP 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 98 98 💬
|
| 17 | AMG157 | - | - | - | - | [1] 98 98 💬
|
| 18 | APD334 | - | - | - | - | [5] 93 93, 96, 97, 98, 269 💬
|
| 19 | APT-1011 | - | - | - | - | [1] 98 98 💬
|
| 20 | APT-1011 - 3 mg | - | - | - | - | [1] 98 98 💬
|
| 21 | APT-1011 3 mg HS | - | - | - | - | [1] 98 98 💬
|
| 22 | AQ280 | - | - | - | - | [1] 98 98 💬
|
| 23 | AQ280 Capsule | - | - | - | - | [1] 98 98 💬
|
| 24 | AQ280 Tablet for Oral Suspension | - | - | - | - | [1] 98 98 💬
|
| 25 | AR401959 L-arginine | [2] Arginine Arginine, L-arginine | [3] Arginine hydrochloride
Arginine hydrochloride
,
Arginine
,
Arginine hydrochloride
💬
| - | - | [3] 96 96, 97, 98 💬
|
| 26 | Arginine | [1] Arginine Arginine | [3] Arginine hydrochloride
Arginine hydrochloride
,
Arginine
,
Arginine hydrochloride
💬
| - | - | [16] 2 2, 21, 46, 57, 58, 67, 72, 96, 97, 98, 113, 210, 223, 225, 251, 299 💬
|
| 27 | Baked Milk | - | - | - | - | [1] 98 98 💬
|
| 28 | Barium | [1] Barium Barium | - | - | - | [5] 2 2, 6, 19, 97, 98 💬
|
| 29 | Barzolvolimab | [1] Barzolvolimab Barzolvolimab | [1] Barzolvolimab
Barzolvolimab
💬
| [1] KIT KIT 💬
| [11] Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | [1] 98 98 💬
|
| 30 | Beclomethasone dipropionate | [1] Beclomethasone dipropionate Beclomethasone dipropionate | [3] Beclomethasone dipropionate
Beclomethasone dipropionate
,
Beclometasone
,
Beclomethasone dipropionate monohydrate
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [2] 97 97, 98 💬
|
| 31 | Behavioral: six-foods elimination diet | - | - | - | - | [1] 98 98 💬
|
| 32 | Benralizumab | [1] Benralizumab Benralizumab | [1] Benralizumab
Benralizumab
💬
| [1] IL5RA IL5RA 💬
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | [5] 44 44, 45, 98, 162, 299 💬
|
| 33 | Bethanechol | [1] Bethanechol Bethanechol | [1] Bethanechol chloride
Bethanechol chloride
💬
| [5] CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬
| [14] Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | [1] 98 98 💬
|
| 34 | Blood sampling | - | - | - | - | [15] 2 2, 3, 13, 14, 17, 46, 51, 64, 86, 96, 97, 98, 106, 162, 300 💬
|
| 35 | BT-11 high | - | - | - | - | [1] 98 98 💬
|
| 36 | BT-11 low | - | - | - | - | [1] 98 98 💬
|
| 37 | BUDESONIDE | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [10] 66 66, 93, 94, 95, 96, 97, 98, 223, 228, 299 💬
|
| 38 | Budesonide 0.5 mg compresse orodispersibili | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 39 | Budesonide 0.5 mg orodispersible tablets | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 40 | Budesonide 0.5mg orodispersible tablet twice daily | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 41 | Budesonide 1 mg compresse orodispersibili | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 42 | Budesonide 1 mg orodispersible tablets | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 43 | Budesonide 1 mg orodispersible tablets (BUL 1 mg) | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 44 | Budesonide 1mg orodispersible tablet twice daily | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 45 | Budesonide 2 mg orodispersible tablets (BUL 2 mg) | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 46 | Budesonide [0.4mg/ml] viscous suspension | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 47 | Budesonide Gel | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 48 | Budesonide oral suspension | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 49 | Budesonide oral suspension [0.2 mg/ml] | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 50 | Budesonide Orodispersible Tablets (Jorveza) | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 51 | Budesonide plus Prevacid | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 52 | BUET 0.5 mg | - | - | - | - | [1] 98 98 💬
|
| 53 | BUET 1 mg | - | - | - | - | [1] 98 98 💬
|
| 54 | BUET 1mg | - | - | - | - | [1] 98 98 💬
|
| 55 | BUET 2mg | - | - | - | - | [1] 98 98 💬
|
| 56 | BUL 0.5 mg | - | - | - | - | [1] 98 98 💬
|
| 57 | BUL 1 mg | - | - | - | - | [1] 98 98 💬
|
| 58 | BUU 0.4mg/ml | - | - | - | - | [1] 98 98 💬
|
| 59 | CALY-002 | [1] CALY-002 CALY-002 | - | - | - | [1] 98 98 💬
|
| 60 | CC-93538 | - | - | - | - | [1] 98 98 💬
|
| 61 | CDX-0159 | - | - | - | - | [1] 98 98 💬
|
| 62 | Cendakimab | [1] Cendakimab Cendakimab | [1] Cendakimab
Cendakimab
💬
| [1] IL13 IL13 💬
| [8] Asthma Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬 | [1] 98 98 💬
|
| 63 | Citalopram | [1] Citalopram Citalopram | [2] Citalopram hydrobromide
Citalopram hydrobromide
,
Citalopram
💬
| [1] SLC6A4 SLC6A4 💬
| [3] Neuroactive ligand signaling Neuroactive ligand signaling, Serotonergic synapse, Synaptic vesicle cycle 💬 | [7] 6 6, 8, 13, 18, 46, 98, 127 💬
|
| 64 | Compressa effervescente 0,5 mg di budesonide per uso orodispersibile | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 65 | Compressa effervescente 1 mg di budesonide per uso orodispersibile | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 66 | CYP substrates | - | - | - | - | [1] 98 98 💬
|
| 67 | Dexlansoprazole | [1] Dexlansoprazole Dexlansoprazole | [2] Dexlansoprazole
Dexlansoprazole
,
Dexlansoprazole sesquihydrate
💬
| [2] ATP4A ATP4A, ATP4B 💬
| [3] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬 | [1] 98 98 💬
|
| 68 | Diagnostic Test: Barium Esophagram | [1] Barium Barium | - | - | - | [1] 98 98 💬
|
| 69 | Diagnostic Test: Bone Mineral Density (DEXA) scan | - | - | - | - | [1] 98 98 💬
|
| 70 | Diagnostic Test: Cortisol level | - | - | - | - | [1] 98 98 💬
|
| 71 | Diagnostic Test: Endoscopy while on study drug | - | - | - | - | [1] 98 98 💬
|
| 72 | Diagnostic Test: esophagogastroduodenoscopy (EGD), buccal swab, blood withdrawal | - | - | - | - | [1] 98 98 💬
|
| 73 | Diagnostic Test: Gastrointestinal Quality of Life index | - | - | - | - | [1] 98 98 💬
|
| 74 | Diagnostic Test: Height measurement | - | - | - | - | [1] 98 98 💬
|
| 75 | Diagnostic Test: High-resolution manometry | - | - | - | - | [1] 98 98 💬
|
| 76 | Diagnostic Test: Physical Examination and Questionnaires | - | - | - | - | [1] 98 98 💬
|
| 77 | Diagnostic Test: Retrospective evaluation of endoscopy prior to study drug | - | - | - | - | [1] 98 98 💬
|
| 78 | Diagnostic Test: Serum biomarkers | - | - | - | - | [1] 98 98 💬
|
| 79 | Diagnostic Test: SPECT/CT Imaging | - | - | - | - | [1] 98 98 💬
|
| 80 | Diagnostic Test: Vitamin D Measurement | [1] Vitamin D Vitamin D | - | - | - | [1] 98 98 💬
|
| 81 | Dose | - | - | - | - | [1] 98 98 💬
|
| 82 | Dupilumab | [1] Dupilumab Dupilumab | [1] Dupilumab
Dupilumab
💬
| [1] IL4R IL4R 💬
| [8] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | [8] 51 51, 97, 98, 160, 162, 222, 300, 306 💬
|
| 83 | Dupilumab (blinded) | [1] Dupilumab Dupilumab | [1] Dupilumab
Dupilumab
💬
| [1] IL4R IL4R 💬
| [8] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | [1] 98 98 💬
|
| 84 | Dupilumab (open-label) | [1] Dupilumab Dupilumab | [1] Dupilumab
Dupilumab
💬
| [1] IL4R IL4R 💬
| [8] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | [1] 98 98 💬
|
| 85 | Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] | [1] Dupilumab Dupilumab | [1] Dupilumab
Dupilumab
💬
| [1] IL4R IL4R 💬
| [8] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | [1] 98 98 💬
|
| 86 | Dupixent | - | - | - | - | [3] 98 98, 160, 162 💬
|
| 87 | Else nutrition formula | - | - | - | - | [1] 98 98 💬
|
| 88 | Eosinophilic Esophagitis (E0E) food introduction-2nd | - | - | - | - | [1] 98 98 💬
|
| 89 | Eosinophilic Esophagitis (EoE) food introduction-1st | - | - | - | - | [1] 98 98 💬
|
| 90 | Eosinophilic Esophagitis (EoE) Food introduction-3rd dose | - | - | - | - | [1] 98 98 💬
|
| 91 | EP-104GI | - | - | - | - | [1] 98 98 💬
|
| 92 | ESO-101 | - | - | - | - | [1] 98 98 💬
|
| 93 | Esomeprazole | [1] Esomeprazole Esomeprazole | [5] Esomeprazole magnesium
Esomeprazole magnesium
,
Esomeprazole sodium
,
Esomeprazole
,
Esomeprazole strontium
,
Esomeprazole magnesium dihydrate
💬
| [2] ATP4A ATP4A, ATP4B 💬
| [3] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬 | [10] 6 6, 13, 46, 86, 98, 107, 113, 234, 298, 299 💬
|
| 94 | EsophaCap | - | - | - | - | [1] 98 98 💬
|
| 95 | Esophageal biopsies | - | - | - | - | [1] 98 98 💬
|
| 96 | Esophageal dilation | - | - | - | - | [1] 98 98 💬
|
| 97 | Esophagogastroduodenoscopy | - | - | - | - | [1] 98 98 💬
|
| 98 | Etrasimod | [1] Etrasimod Etrasimod | [2] Etrasimod
Etrasimod
,
Etrasimod arginine
💬
| [3] S1PR1 S1PR1, S1PR4, S1PR5 💬
| [4] Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | [3] 96 96, 97, 98 💬
|
| 99 | Etrasimod L-arginine | [3] Arginine Arginine, Etrasimod, L-arginine | [5] Arginine hydrochloride
Arginine hydrochloride
,
Arginine
,
Arginine hydrochloride
,
Etrasimod
,
Etrasimod arginine
💬
| [3] S1PR1 S1PR1, S1PR4, S1PR5 💬
| [4] Efferocytosis Efferocytosis, FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | [3] 96 96, 97, 98 💬
|
| 100 | EUR-1100 | - | - | - | - | [1] 98 98 💬
|
| 101 | Famotidine | [1] Famotidine Famotidine | [1] Famotidine
Famotidine
💬
| [1] HRH2 HRH2 💬
| [4] Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction 💬 | [7] 6 6, 46, 86, 98, 107, 145, 300 💬
|
| 102 | Fasenra | - | - | - | - | [5] 44 44, 45, 98, 162, 299 💬
|
| 103 | Florence 30 µg/mL | - | - | - | - | [1] 98 98 💬
|
| 104 | Florence 60 µg/mL | - | - | - | - | [1] 98 98 💬
|
| 105 | Florence 90 µg/mL | - | - | - | - | [1] 98 98 💬
|
| 106 | Flovent | - | - | - | - | [1] 98 98 💬
|
| 107 | Fluticasone | [1] Fluticasone Fluticasone | [1] Fluticasone
Fluticasone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [4] 98 98, 228, 299, 306 💬
|
| 108 | Fluticasone MDI | [1] Fluticasone Fluticasone | [1] Fluticasone
Fluticasone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 109 | FLUTICASONE PROPIONATE | [2] Fluticasone Fluticasone, Fluticasone propionate | [2] Fluticasone propionate
Fluticasone propionate
,
Fluticasone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [3] 98 98, 228, 306 💬
|
| 110 | Fluticasone Propionate, 800 mcg twice daily (post 4FED failure) | [2] Fluticasone Fluticasone, Fluticasone propionate | [2] Fluticasone propionate
Fluticasone propionate
,
Fluticasone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 111 | Fluticasone Propionate, 880 mcg twice daily (after 6FED failure) | [2] Fluticasone Fluticasone, Fluticasone propionate | [2] Fluticasone propionate
Fluticasone propionate
,
Fluticasone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 112 | Fluticasone Propionate, USP | [2] Fluticasone Fluticasone, Fluticasone propionate | [2] Fluticasone propionate
Fluticasone propionate
,
Fluticasone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 113 | Gold | [1] Gold Gold | - | - | - | [71] 2 2, 5, 6, 11, 13, 17, 19, 21, 22, 28, 34, 35, 46, 49, 50, 53, 54, 56, 57, 58, 60, 63, 64, 65, 66, 68, 71, 75, 76, 77, 79, 84, 85, 86, 88, 91, 93, 95, 96, 97, 98, 107, 113, 127, 137, 158, 162, 167, 171, 193, 206, 215, 218, 222, 223, 224, 226, 227, 228, 230, 235, 271, 291, 294, 296, 298, 299, 310, 318, 331, 340 💬
|
| 114 | High dose budesonide suspension | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 115 | High dose budesonide tablet | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 116 | Honey | [1] Honey Honey | [1] Honey
Honey
💬
| - | - | [4] 57 57, 63, 98, 230 💬
|
| 117 | Humanised IgG1k monoclonal antibody against KIT | - | - | - | - | [1] 98 98 💬
|
| 118 | Infliximab | [1] Infliximab Infliximab | [1] Infliximab
Infliximab
💬
| [1] TNF TNF 💬
| [66] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [27] 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
|
| 119 | Inhaled/swallowed budesonide | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 120 | Intraluminal Impedance | - | - | - | - | [1] 98 98 💬
|
| 121 | Intubated with Propofol (IP) | [1] Propofol Propofol | [1] Propofol
Propofol
💬
| [16] GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬
| [9] Cadherin signaling Cadherin signaling, GABAergic synapse, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | [1] 98 98 💬
|
| 122 | Intubated with Sevoflurane (IS) | [1] Sevoflurane Sevoflurane | [1] Sevoflurane
Sevoflurane
💬
| - | - | [1] 98 98 💬
|
| 123 | IRL201104 | - | - | - | - | [1] 98 98 💬
|
| 124 | Jorveza | - | - | - | - | [1] 98 98 💬
|
| 125 | Jorveza 0.5 mg compresse orodispersibili | - | - | - | - | [1] 98 98 💬
|
| 126 | Jorveza 0.5 mg orodispersible tablets | - | - | - | - | [1] 98 98 💬
|
| 127 | Jorveza 1 mg compresse orodispersibili | - | - | - | - | [1] 98 98 💬
|
| 128 | Jorveza 1 mg orodispersible tablets | - | - | - | - | [1] 98 98 💬
|
| 129 | L-arginine | [2] Arginine Arginine, L-arginine | [3] Arginine hydrochloride
Arginine hydrochloride
,
Arginine
,
Arginine hydrochloride
💬
| - | - | [10] 2 2, 21, 46, 67, 96, 97, 98, 113, 223, 299 💬
|
| 130 | Lansoprazole | [1] Lansoprazole Lansoprazole | [1] Lansoprazole
Lansoprazole
💬
| [2] ATP4A ATP4A, ATP4B 💬
| [3] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬 | [8] 63 63, 71, 85, 98, 166, 222, 223, 299 💬
|
| 131 | Lirentelimab | [1] Lirentelimab Lirentelimab | [1] Lirentelimab
Lirentelimab
💬
| - | - | [1] 98 98 💬
|
| 132 | Lirentelimab (AK002) | [1] Lirentelimab Lirentelimab | [1] Lirentelimab
Lirentelimab
💬
| - | - | [1] 98 98 💬
|
| 133 | Loratadine | [1] Loratadine Loratadine | [1] Loratadine
Loratadine
💬
| [1] HRH1 HRH1 💬
| [4] Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction 💬 | [5] 13 13, 19, 46, 89, 98 💬
|
| 134 | Losartan | [1] Losartan Losartan | [2] Losartan potassium
Losartan potassium
,
Losartan
💬
| [1] AGTR1 AGTR1 💬
| [17] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | [20] 17 17, 19, 36, 46, 57, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 223, 299 💬
|
| 135 | LOSARTAN POTASSIUM | [2] Losartan Losartan, Potassium | [3] Losartan potassium
Losartan potassium
,
Losartan
,
Potassium
💬
| [1] AGTR1 AGTR1 💬
| [17] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | [5] 36 36, 98, 167, 179, 215 💬
|
| 136 | Low dose budesonide tablet | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 137 | MEDI-563 | - | - | - | - | [5] 44 44, 45, 98, 162, 299 💬
|
| 138 | MEDI9929 anti-TSLP mAb (AMG157) | [1] Tezepelumab Tezepelumab | [1] Tezepelumab
Tezepelumab
💬
| [1] TSLP TSLP 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 98 98 💬
|
| 139 | MEPOLIZUMAB | [1] Mepolizumab Mepolizumab | [1] Mepolizumab
Mepolizumab
💬
| [1] IL5 IL5 💬
| [13] Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | [4] 44 44, 45, 98, 162 💬
|
| 140 | Mepolizumab 100 mg | [1] Mepolizumab Mepolizumab | [1] Mepolizumab
Mepolizumab
💬
| [1] IL5 IL5 💬
| [13] Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | [1] 98 98 💬
|
| 141 | Mepolizumab 300 mg | [1] Mepolizumab Mepolizumab | [1] Mepolizumab
Mepolizumab
💬
| [1] IL5 IL5 💬
| [13] Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | [3] 44 44, 45, 98 💬
|
| 142 | Mesalamine Oral Product | - | - | - | - | [1] 98 98 💬
|
| 143 | Mometasone | [1] Mometasone Mometasone | [1] Mometasone
Mometasone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [2] 98 98, 162 💬
|
| 144 | MOMETASONE FUROATE | [2] Mometasone Mometasone, Mometasone furoate | [3] Mometasone furoate
Mometasone furoate
,
Mometasone furoate hydrate
,
Mometasone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [2] 98 98, 162 💬
|
| 145 | Montelukast | [1] Montelukast Montelukast | [2] Montelukast sodium
Montelukast sodium
,
Montelukast
💬
| [1] CYSLTR1 CYSLTR1 💬
| [2] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | [10] 6 6, 13, 19, 46, 61, 63, 85, 98, 222, 228 💬
|
| 146 | Montelukast/ Singulair | [1] Montelukast Montelukast | [2] Montelukast sodium
Montelukast sodium
,
Montelukast
💬
| [1] CYSLTR1 CYSLTR1 💬
| [2] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 147 | Nasonex | - | - | - | - | [1] 98 98 💬
|
| 148 | NDX-3315 | [1] NDX-3315 NDX-3315 | - | - | - | [1] 98 98 💬
|
| 149 | NDX-3324 | - | - | - | - | [1] 98 98 💬
|
| 150 | NIOX MINO® Airway Inflammation Monitor | - | - | - | - | [1] 98 98 💬
|
| 151 | Nitric Oxide | [1] Nitric Oxide Nitric Oxide | [1] Nitric oxide
Nitric oxide
💬
| - | - | [12] 46 46, 51, 85, 86, 88, 97, 98, 210, 251, 294, 299, 340 💬
|
| 152 | OC000459 | - | - | - | - | [1] 98 98 💬
|
| 153 | OMALIZUMAB | [1] Omalizumab Omalizumab | [1] Omalizumab
Omalizumab
💬
| [1] FCER1A FCER1A 💬
| [4] Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | [7] 46 46, 53, 65, 98, 162, 226, 299 💬
|
| 154 | Omeprazole | [1] Omeprazole Omeprazole | [3] Omeprazole
Omeprazole
,
Omeprazole sodium
,
Omeprazole magnesium
💬
| [2] ATP4A ATP4A, ATP4B 💬
| [3] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬 | [18] 6 6, 8, 13, 21, 46, 51, 67, 85, 90, 96, 97, 98, 225, 271, 282, 294, 298, 299 💬
|
| 155 | Omeprazole 20 MG Oral Tablet | [1] Omeprazole Omeprazole | [3] Omeprazole
Omeprazole
,
Omeprazole sodium
,
Omeprazole magnesium
💬
| [2] ATP4A ATP4A, ATP4B 💬
| [3] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬 | [1] 98 98 💬
|
| 156 | Omeprazole 20mg BID | [1] Omeprazole Omeprazole | [3] Omeprazole
Omeprazole
,
Omeprazole sodium
,
Omeprazole magnesium
💬
| [2] ATP4A ATP4A, ATP4B 💬
| [3] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬 | [1] 98 98 💬
|
| 157 | Ondansetron | [1] Ondansetron Ondansetron | [2] Ondansetron
Ondansetron
,
Ondansetron hydrochloride hydrate
💬
| [5] HTR3A HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬
| [3] Neuroactive ligand signaling Neuroactive ligand signaling, Serotonergic synapse, Taste transduction 💬 | [5] 6 6, 97, 98, 107, 231 💬
|
| 158 | Oral Budesonide | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [2] 97 97, 98 💬
|
| 159 | Oral Budesonide Suspension (MB-9) | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 160 | Oral Budesonide Suspension (OBS) | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 161 | Oral cromolyn sodium | - | - | - | - | [1] 98 98 💬
|
| 162 | Oral Viscous Budesonide | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 163 | Oral Viscous Budesonide (OVB) | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 164 | Other: 1 Food Elimination Diet | - | - | - | - | [1] 98 98 💬
|
| 165 | Other: 1 Food Elimination Diet Therapy | - | - | - | - | [1] 98 98 💬
|
| 166 | Other: 4 Food Elimination Diet | - | - | - | - | [1] 98 98 💬
|
| 167 | Other: 4 Food Elimination Diet (post 1FED failure) | - | - | - | - | [1] 98 98 💬
|
| 168 | Other: 6 Food Elimination Diet (after 1FED failure) | - | - | - | - | [1] 98 98 💬
|
| 169 | Other: 6 Food Elimination Diet Therapy | - | - | - | - | [1] 98 98 💬
|
| 170 | Other: Antigen (wheat base soy sauce) spray | [1] Wheat Wheat | [1] Wheat
Wheat
💬
| - | - | [1] 98 98 💬
|
| 171 | Other: Assessment of medication compliance | - | - | - | - | [1] 98 98 💬
|
| 172 | Other: Biopsy samples | - | - | - | - | [1] 98 98 💬
|
| 173 | Other: Blood Samples | - | - | - | - | [13] 3 3, 13, 46, 51, 53, 63, 85, 86, 88, 96, 98, 140, 193 💬
|
| 174 | Other: D-xylose | [1] Xylose Xylose | [1] Xylose
Xylose
💬
| - | - | [1] 98 98 💬
|
| 175 | Other: Elimination diet | - | - | - | - | [1] 98 98 💬
|
| 176 | Other: Formalin-fixed Paraffin-embedded (FFPE) tissue samples analysis | - | - | - | - | [1] 98 98 💬
|
| 177 | Other: Honey | [1] Honey Honey | [1] Honey
Honey
💬
| - | - | [1] 98 98 💬
|
| 178 | Other: Matching vehicle control | - | - | - | - | [1] 98 98 💬
|
| 179 | Other: Medication Compliance Phone Call | - | - | - | - | [1] 98 98 💬
|
| 180 | Other: Oral Nitric Oxide testing | [1] Nitric Oxide Nitric Oxide | [1] Nitric oxide
Nitric oxide
💬
| - | - | [1] 98 98 💬
|
| 181 | Other: Saline | - | - | - | - | [8] 2 2, 6, 46, 97, 98, 256, 274, 301 💬
|
| 182 | Other: Symptom Survey | - | - | - | - | [1] 98 98 💬
|
| 183 | Other: Xanthan Gum | [1] Xanthan gum Xanthan gum | [1] Xanthan gum
Xanthan gum
💬
| - | - | [1] 98 98 💬
|
| 184 | Potassium | [1] Potassium Potassium | [1] Potassium
Potassium
💬
| - | - | [17] 36 36, 46, 57, 58, 66, 67, 88, 93, 94, 97, 98, 115, 167, 179, 215, 223, 235 💬
|
| 185 | Propofol | [1] Propofol Propofol | [1] Propofol
Propofol
💬
| [16] GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬
| [9] Cadherin signaling Cadherin signaling, GABAergic synapse, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | [10] 3 3, 6, 21, 22, 34, 46, 70, 97, 98, 296 💬
|
| 186 | QAX576 | - | - | - | - | [4] 51 51, 85, 96, 98 💬
|
| 187 | Radiation: Computerized Tomography scan | - | - | - | - | [1] 98 98 💬
|
| 188 | Radiation: Esophageal Barium Xray | [1] Barium Barium | - | - | - | [1] 98 98 💬
|
| 189 | Radiation: Planar Images | - | - | - | - | [1] 98 98 💬
|
| 190 | Radiation: Single Photon Emission Computed Tomography scans | - | - | - | - | [1] 98 98 💬
|
| 191 | Reslizumab | [1] Reslizumab Reslizumab | [1] Reslizumab
Reslizumab
💬
| [1] IL5 IL5 💬
| [13] Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | [2] 44 44, 98 💬
|
| 192 | RPC4046 | - | - | - | - | [1] 98 98 💬
|
| 193 | SB-240563 | - | - | - | - | [3] 44 44, 45, 98 💬
|
| 194 | SCH55700 | - | - | - | - | [1] 98 98 💬
|
| 195 | Sevoflurane | [1] Sevoflurane Sevoflurane | [1] Sevoflurane
Sevoflurane
💬
| - | - | [8] 6 6, 21, 22, 34, 70, 98, 225, 296 💬
|
| 196 | Sirolimus | [1] Sirolimus Sirolimus | [1] Sirolimus
Sirolimus
💬
| [1] MTOR MTOR 💬
| [52] AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, Integrated stress response (ISR) signaling pathway, Integrin signaling, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, Lysosome biogenesis, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | [46] 6 6, 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
|
| 197 | Solrikitug | [1] Solrikitug Solrikitug | [1] Solrikitug
Solrikitug
💬
| [1] CRLF2 CRLF2 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 98 98 💬
|
| 198 | Solrikitug High Dose | [1] Solrikitug Solrikitug | [1] Solrikitug
Solrikitug
💬
| [1] CRLF2 CRLF2 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 98 98 💬
|
| 199 | Solrikitug Low Dose | [1] Solrikitug Solrikitug | [1] Solrikitug
Solrikitug
💬
| [1] CRLF2 CRLF2 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 98 98 💬
|
| 200 | Solrikitug Mid Dose | [1] Solrikitug Solrikitug | [1] Solrikitug
Solrikitug
💬
| [1] CRLF2 CRLF2 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 98 98 💬
|
| 201 | Steroid and Proton Pump Inhibitor Therapy | - | - | - | - | [1] 98 98 💬
|
| 202 | Stool sampling | - | - | - | - | [2] 97 97, 98 💬
|
| 203 | Sucralfate | [1] Sucralfate Sucralfate | [1] Sucralfate
Sucralfate
💬
| - | - | [1] 98 98 💬
|
| 204 | Swallowed fluticasone | [1] Fluticasone Fluticasone | [1] Fluticasone
Fluticasone
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 205 | Technetium Tc 99M | - | - | - | - | [1] 98 98 💬
|
| 206 | Tezepelumab | [1] Tezepelumab Tezepelumab | [1] Tezepelumab
Tezepelumab
💬
| [1] TSLP TSLP 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [3] 44 44, 45, 98 💬
|
| 207 | Tezepelumab APFS | [1] Tezepelumab Tezepelumab | [1] Tezepelumab
Tezepelumab
💬
| [1] TSLP TSLP 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 98 98 💬
|
| 208 | Tezepelumab via APFS | [1] Tezepelumab Tezepelumab | [1] Tezepelumab
Tezepelumab
💬
| [1] TSLP TSLP 💬
| [2] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | [1] 98 98 💬
|
| 209 | Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms | [1] Lansoprazole Lansoprazole | [1] Lansoprazole
Lansoprazole
💬
| [2] ATP4A ATP4A, ATP4B 💬
| [3] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬 | [1] 98 98 💬
|
| 210 | Unstimulated saliva sampling | - | - | - | - | [1] 98 98 💬
|
| 211 | Upadacitinib | [1] Upadacitinib Upadacitinib | [3] Upadacitinib
Upadacitinib
,
Upadacitinib tartrate
,
Upadacitinib hydrate
💬
| [1] JAK1 JAK1 💬
| [27] Coronavirus disease Coronavirus disease, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | [12] 40 40, 41, 46, 49, 53, 55, 63, 96, 97, 98, 107, 271 💬
|
| 212 | Upadacitinib 30mg Dose | [1] Upadacitinib Upadacitinib | [3] Upadacitinib
Upadacitinib
,
Upadacitinib tartrate
,
Upadacitinib hydrate
💬
| [1] JAK1 JAK1 💬
| [27] Coronavirus disease Coronavirus disease, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | [1] 98 98 💬
|
| 213 | Urine sampling | - | - | - | - | [1] 98 98 💬
|
| 214 | Viaskin Milk 500 mcg | - | - | - | - | [1] 98 98 💬
|
| 215 | Viscous/swallowed budesonide | [1] Budesonide Budesonide | [1] Budesonide
Budesonide
💬
| [1] NR3C1 NR3C1 💬
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 98 98 💬
|
| 216 | Vitamin D | [1] Vitamin D Vitamin D | - | - | - | [26] 3 3, 6, 13, 15, 19, 41, 43, 44, 46, 49, 50, 68, 74, 93, 95, 96, 97, 98, 179, 222, 228, 235, 256, 274, 298, 299 💬
|
| 217 | Vonoprazan | [1] Vonoprazan Vonoprazan | [1] Vonoprazan
Vonoprazan
💬
| [2] ATP4A ATP4A, ATP4B 💬
| [3] Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Oxidative phosphorylation 💬 | [3] 63 63, 97, 98 💬
|
| 218 | Wheat | [1] Wheat Wheat | [1] Wheat
Wheat
💬
| - | - | [5] 6 6, 53, 97, 98, 266 💬
|
| 219 | Xanthan gum | [1] Xanthan gum Xanthan gum | [1] Xanthan gum
Xanthan gum
💬
| - | - | [1] 98 98 💬
|
| 220 | Xylose | [1] Xylose Xylose | [1] Xylose
Xylose
💬
| - | - | [1] 98 98 💬
|
| 221 | Zofran - no intubation | - | - | - | - | [1] 98 98 💬
|